Customers' Choice Reparixin, Cxcr1/2 Allosteric Antagonist (tbi2527) Massive 85% Savings [ha89d5fu]

Reparixin: Advanced CXCR1/2 Allosteric Antagonist

Reparixin, a cutting-edge CXCR1/2 allosteric antagonist, stands as a powerful tool in the realm of drug discovery and treatment. This novel compound boasts an impressive profile, offering a noncompetitive inhibition of IL-8 activation of CXCR1 and CXCR2 chemokine receptors. With its unique mechanism of action, Reparixin effectively blocks a range of activities associated with IL-8 signaling, including leukocyte recruitment, without interfering with receptor activation by other CXCR1 and CXCR2 agonists. This versatile antagonist is a game-changer in the treatment of inflammatory diseases and cancer.

Product Specifications and Features

Reparixin is formulated as a high-purity powder, ensuring a reliable and consistent product. Its molecular formula is C₁₄H₂₁NO₃S, with a formula weight of 283.39 and a CAS number of 266359-83-5. The product purity exceeds 98%, guaranteeing the highest quality standards. Reparixin is highly soluble in DMSO, up to 100 mg/ml, and in ethanol, up to 25 mg/ml, making it easy to handle and incorporate into various experimental protocols. With a storage temperature of -20°C and stability of ≥ 1 year, Reparixin is a reliable choice for researchers and pharmaceutical developers.

Applications and Benefits

Reparixin's multifaceted applications make it a valuable asset in both research and clinical settings. Its ability to reduce blood pressure by inhibiting hypertension-related mediators in spontaneously hypertensive rats, as well as its role in attenuating inflammatory responses and promoting recovery after spinal cord trauma, highlights its potential in treating a wide range of conditions. Additionally, Reparixin's blockade of CXCR1 has been shown to deplete cancer stem cell populations in human breast cancer cell lines, offering hope for more effective cancer treatments. This versatile compound is ideal for researchers exploring inflammatory diseases, cancer, and cardiovascular disorders, as well as for pharmaceutical companies seeking innovative therapeutic solutions.